報價延遲最少15分鐘:2025/05/15 05:54 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.24/-0.47
|
|
企業價值
101.82M
|
| 資產負債 |
|
每股賬面淨值
0.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/15 05:54 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon. |